Clinical Trials Browser

Phase 2/3 × Terminated × Gynecologic × Clear all

NCT05870748 2025-09-23

REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

Phase 2/3 Terminated

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06321068 2025-08-14

BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer

Phase 2/3 Terminated

Endometrial Neoplasms

NCT04159155 2025-08-12

CAN-STAMP

Phase 2/3 Terminated

Endometrial Neoplasms, Cystadenocarcinoma, Serous

NCT02641639 2025-03-24

FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With Platinum Resistant Ovarian Cancer

Phase 2/3 Terminated

70 enrolled 16 charts

Platinum Resistant Ovarian Cancer

NCT00003880 2015-04-16

Paclitaxel Plus Carboplatin With or Without SCH-58500 in Treating Patients With Newly Diagnosed Stage III Ovarian or Stage III Primary Peritoneal Cancer

Phase 2/3 Terminated

Carcinoma, Ovarian Epithelial, Ovarian Neoplasms

NCT00418574 2011-11-24

MIMOSA

Phase 2/3 Terminated

888 enrolled 17 charts

Ovarian Neoplasms